Researchers found targeting androgens/AR with either the recently developed antiandrogen Enzalutamide or AR-shRNAs led to increased prostate cancer cell invasion, yet decreased bladder cancer cell invasion.
[Cell Death & Differentiation]
0
Category Archives: Prostate Cell
Prostate Cell NewsProstate Cell News is an online publication and email newsletter summarizing the latest prostate cell research.
Published every week since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.
Targeting Androgen Receptor (AR) with Antiandrogen Enzalutamide Increases Prostate Cancer Cell Invasion Yet Decreases Bladder Cancer Cell Invasion via Differentially Altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 Signals
Androgen Receptor (AR) Heterogeneity in Prostate Cancer and Therapy Resistance
Prostate Cancer Immunotherapy-Finally in from the Cold?
Scientists discuss the promise of immunotherapy in prostate cancer treatment with an emphasis on emerging therapeutic targets. Most prostate tumors have low tumor mutational burden and lack immunogenicity, representing significant hurdles to induction of anti-tumor immunity.
[Current Oncology Reports]
0
Novartis 177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival for Men with Metastatic Castration-Resistant Prostate Cancer in Phase III VISION Study
Novartis AG announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated significant improvement in overall survival compared to SOC alone, in patients with progressive PSMA-positive metastatic CRPC.
[Novartis AG]
0
Francis Medical Announces Positive Data from VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
Francis Medical, Inc. announced positive results from the company’s VAPOR 1 clinical study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for treating prostate cancer.
[Francis Medical, Inc.]
0
HGK Promotes Metastatic Dissemination in Prostate Cancer
Investigators showed that genetic deletion of MAP4K4 or pharmacological inhibition of its encoded kinase, HGK, inhibited metastatic prostate cancer cells migration and clonogenic properties.
[Scientific Reports]
0
AR-mTOR-SRF Axis Regulates HMMR Expression in Human Prostate Cancer Cells
The authors reported that mammalian target of rapamycin (mTOR) is a key regulator of hyaluronan-mediated motility receptor (HMMR) expression, for which its kinase activity is required. Pharmacological inhibitors of mTOR markedly suppressed the mRNA level as well as the protein level of HMMR in LNCaP and PC-3 cells.
[Biomolecules & Therapeutics]
0
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro
NUC-1031 preferentially targeted leukemic stem cells in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP..
[Journal of Medicinal Chemistry]
0
An Improved 211At-Labeled Agent for PSMA-Targeted Alpha Therapy
211At-VK-02-90-Lu was selected and evaluated in cell uptake and internalization studies, biodistribution and prostate-specific membrane antigen (PSMA)+ PC3 PIP tumor growth control in experimental flank and metastatic models.
[Journal of Nuclear Medicine]
0
Induction of Monoamine Oxidase A-Mediated Oxidative Stress and Impairment of NRF2-Antioxidant Defence Response by Polyphenol-Rich Fraction of Bergenia ligulata Sensitizes Prostate Cancer Cells In Vitro and In Vivo
Researchers explored anti-prostate cancer activity in a polyphenol-rich fraction of Bergenia ligulata, a plant used in Indian traditional and folk medicine for its anti-inflammatory and antineoplastic properties.
[Free Radical Biology and Medicine]
0
RANKL Immunization Inhibits Prostate Cancer Metastasis by Modulating EMT through a RANKL-Dependent Pathway
The authors used preclinical experimental models to investigate whether an inactive form of receptor activator of nuclear factor kappa-B ligand (RANKL) affected bone metastasis in RANKL-induced prostate cancer.
[Scientific Reports]
0
